Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.
We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally.
In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”. As a founder and […]
Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize. The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in […]
Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. HEMEX AG is a privately-owned Swiss investment and consulting company headquartered […]
After the Top 16 was announced by the W.A. De Vigier in March, now the Top 10 finalists for this year’s Award are published. The winners will be announced in early June! We are particularly proud to see our portfolio company Annaida Technologies in the Top 10 and wish them and all the Top 10 Startups […]
- 1
- 2